Teprotumumab for the Treatment of Active Thyroid Eye Disease

Raymond S. Douglas,George J. Kahaly,Amy Patel,Saba Sile,Elizabeth H. Z. Thompson,Renee Perdok,James C. Fleming,Brian T. Fowler,Claudio Marcocci,Michele Marinò,Alessandro Antonelli,Roger A. Dailey,Gerald J. Harris,Anja Eckstein,Jade S. Schiffman,Rosa A. Tang,Christine C. Nelson,Mario Salvi,Sara T. Wester,Jeffrey W. Sherman,Thomas Vescio,Robert J. Holt,Terry J. Smith

Teprotumumab for the Treatment of Active Thyroid Eye Disease

2020

Abstract Background Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration–approved medical therapy is available...

Keywords:

Surgery
Dermatology
Drug
medical therapy
Diabetes mellitus
Medicine
Blinding
Teprotumumab
Thyroid
Eye disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

147

Citations